Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annu…

<p xmlns="https://www.w3.org/1999/xhtml"><span class="xn-location">DUBLIN, <span class="xn-chron">May 3, 2021 /PRNewswire/ – <span class="xn-org">Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4, multi-center, open-label study to assess the efficacy and safety of Acthar<sup>®</sup> Gel…

Related post